List of Excipients in Branded Drug MULTIHANCE

MultiHance Excipient Strategy and Commercial Opportunities in Gadolinium-Based MRI Contrast

Last updated: August 27, 2026

MultiHance, the branded gadolinium-based contrast agent containing gadobenate dimeglumine, uses a low-complexity injectable formulation. Its commercial value is driven less by excipient innovation than by formulation reliability, sterile manufacturing, imaging performance, regulatory compliance, supply continuity, and hospital purchasing economics. The main opportunity for manufacturers is a compliant generic or authorized-generic platform with equivalent gadolinium delivery, reduced manufacturing cost, broader presentation options, and dependable supply.

What is MultiHance and how is it regulated?

MultiHance is an intravenous MRI contrast agent containing gadobenate dimeglumine at a concentration equivalent to 0.5 mmol of gadolinium per milliliter. In the United States, Bracco Diagnostics markets the product under FDA New Drug Application 021357. The FDA-approved labeling identifies use in MRI of the central nervous system, breast, and vascular structures in specified adult populations.[1]

MultiHance product profile

Attribute	MultiHance
Active ingredient	Gadobenate dimeglumine
Gadolinium concentration	0.5 mmol/mL
Dosage form	Sterile intravenous injection
Route	Intravenous
Product type	Gadolinium-based contrast agent
U.S. sponsor	Bracco Diagnostics Inc.
U.S. application	NDA 021357
Key clinical uses	CNS MRI, breast MRI, magnetic resonance angiography
Formulation class	Aqueous, nonpreserved, single-dose injectable
Primary formulation risk	Sterility, particulate control, container closure, chelate stability, dose uniformity

MultiHance is a small-molecule gadolinium chelate rather than a biologic. Biosimilar pathways do not apply. A competing product would generally enter through an abbreviated new drug application or a 505(b)(2) application, depending on the development strategy and the extent of reliance on the reference product.

What excipients are used in MultiHance?

MultiHance has a minimal excipient profile. The U.S. prescribing information identifies water for injection as an inactive ingredient. The formulation is adjusted within a specified pH range, and the product does not depend on a complex buffer, surfactant, antimicrobial preservative, or lyophilization system.[1,2]

MultiHance excipient composition

Formulation component	Function	Commercial significance
Water for injection	Vehicle	Requires pharmaceutical-grade water generation and validated microbial control
pH adjustment system	Maintains formulation pH	Affects tolerability, chelate stability, and release testing
Gadobenate dimeglumine	Active gadolinium chelate	Determines imaging dose, osmolality, and metal-complex stability

The absence of a complex excipient system reduces formulation-design freedom but also lowers the number of technical barriers to a competing product. The critical quality attributes are the gadolinium concentration, chelate identity, pH, osmolality, sterility, endotoxin level, visible and subvisible particles, extractables and leachables, and container closure integrity.

How does the MultiHance excipient strategy affect generic development?

A generic developer would not gain substantial differentiation from substituting conventional excipients. The product’s formulation is already close to the simplest commercially viable architecture for an injectable contrast agent.

The development strategy should therefore prioritize:

1. Matching the reference product’s active concentration and pH.
2. Demonstrating chemical and physical stability through shelf life.
3. Controlling free gadolinium and degradation products.
4. Establishing container compatibility.
5. Supporting a robust sterile filling process.
6. Providing equivalent dose delivery across vial presentations.
7. Avoiding excipient changes that create unnecessary clinical or regulatory questions.

Formulation targets for a competing product

A practical development target would include:

• The same gadolinium concentration as the reference product.
• The same or closely comparable pH range.
• No antimicrobial preservative in single-dose presentations.
• Equivalent or lower particulate burden.
• Comparable osmolality and viscosity.
• Equivalent administration volume at labeled doses.
• Packaging compatible with automated MRI contrast injectors.
• Stability under normal storage and transport conditions.
• No precipitation, discoloration, metal release, or chelate degradation.

For a 505(j) generic, an excipient change can create additional regulatory work if it affects safety, tolerability, stability, or administration. A 505(b)(2) applicant may obtain more flexibility in formulation, but that flexibility comes with a larger clinical and regulatory burden.

What formulation patents protect MultiHance?

The commercial formulation is likely protected primarily by historical composition, use, manufacturing, and formulation patents rather than by a modern excipient platform. The key intellectual-property asset is the gadobenate molecule and its use as a gadolinium-based MRI contrast agent, not a differentiated excipient system.

Patent categories relevant to MultiHance

Patent category	Potential scope	Current commercial relevance
Gadolinium-chelate composition patents	Chemical structure and salts	Core composition protection is historically old and likely limited by expiration in major markets
MRI diagnostic-use patents	CNS, liver, breast, vascular, or other imaging uses	May remain relevant where specific claims are listed or enforceable
Manufacturing patents	Chelation, purification, isolation, or scale-up	Can create process barriers if claims remain active
Formulation patents	Concentration, pH, stability, or packaging	Less likely to be central if the formulation is simple
Device or presentation patents	Syringes, injectors, or administration systems	Potentially relevant to differentiated commercial presentations
Label-related patents	Approved method-of-use claims	Relevant to paragraph IV and skinny-label analysis

A current Orange Book review is required to determine whether any active U.S. patents are listed against NDA 021357 and whether those patents cover the formulation, method of use, or other aspects of MultiHance. The commercial analysis should separate listed patents from unlisted patents, regulatory exclusivity, and patents enforceable outside the United States.

When does MultiHance lose exclusivity?

MultiHance’s principal U.S. regulatory exclusivity dates are historical. The product was approved in 2004, so any standard five-year new chemical entity exclusivity would have ended years ago if applicable. Any three-year exclusivity associated with later clinical supplements would also have expired based on the product’s approval history.[1,3]

Patent protection is a separate question. A generic applicant must assess:

• Whether any patents are listed in the FDA Orange Book.
• The expiration date of each listed patent.
• Whether pediatric exclusivity extends a listed patent.
• Whether the proposed label includes a patented indication.
• Whether a paragraph IV certification is required.
• Whether unlisted process or formulation patents create litigation exposure.
• Whether patent settlements restrict launch timing.

The absence of a current active regulatory exclusivity period does not eliminate patent risk. Conversely, expired composition patents do not necessarily establish freedom to operate for a specific indication, manufacturing route, injector presentation, or formulation.

What is the Orange Book status of MultiHance?

MultiHance is associated with FDA NDA 021357. The Orange Book is the relevant U.S. source for identifying any patents and exclusivity associated with the approved application.[3]

For a generic applicant, the Orange Book analysis should record:

Review item	Required assessment
Reference listed drug	MultiHance under NDA 021357
Dosage form	Injectable solution
Route	Intravenous
Strength	0.5 mmol gadolinium/mL
Patent listings	Confirm current listed patents and expiration dates
Use codes	Review each listed method-of-use description
Exclusivity	Confirm whether any remaining exclusivity applies
Certification	Paragraph I, II, III, or IV, depending on listed patents
Label strategy	Full label or permissible carve-out

A paragraph IV challenge would be most commercially attractive if no active composition patent blocks the product and any method-of-use patents can be carved out without compromising the major commercial indications. A full-label generic would have greater market access but potentially greater litigation exposure.

What generic entry risks exist for MultiHance?

The largest generic-entry risks are technical and commercial rather than excipient-related.

Technical risks

• Gadolinium-chelate purity and identity.
• Free gadolinium control.
• Stability of the chelate during storage.
• Container closure interaction.
• Silicone oil or stopper-related particulate generation.
• Compatibility with MRI power injectors.
• Sterile manufacturing validation.
• Scale-up from laboratory to commercial fill volumes.

Regulatory risks

• Failure to match reference-product quality attributes.
• Differences in pH, osmolality, or viscosity.
• Incomplete extractables and leachables data.
• Inadequate container closure integrity.
• Questions about indication-specific labeling.
• A 505(b)(2) route becoming necessary because of formulation differences.

Commercial risks

• Hospital contracts with incumbent contrast suppliers.
• Bundled purchasing agreements covering multiple imaging agents.
• Switching costs for radiology departments.
• Distributor inventory requirements.
• Dependence on a small number of sterile injectable facilities.
• Price erosion after multiple generic entrants.
• Limited value in adding conventional excipients.

The likely launch pattern is a price-led injectable generic with limited clinical differentiation. A first entrant could obtain favorable contracting terms, while later entrants would face rapid price compression.

What commercial opportunities exist in MultiHance excipients and presentations?

The strongest opportunities are not new excipients. They are manufacturing, packaging, and workflow improvements.

Ready-to-use and high-throughput presentations

Radiology departments value products that reduce preparation time and medication-handling steps. Commercial opportunities include:

• Larger-volume presentations for high-throughput MRI centers.
• Smaller vials that reduce wastage for low-volume procedures.
• Prefilled syringes, where compatible with the product’s stability and injector systems.
• Presentations optimized for automated dose dispensing.
• Barcoded packaging and electronic inventory controls.
• Unit-dose formats that reduce manipulation and contamination risk.

These products would require careful assessment of container closure, silicone exposure, sterilization, stability, and compatibility with contrast injectors.

Hospital-cost optimization

A competing product can gain share through:

• Lower acquisition cost.
• Reduced vial waste.
• Fewer preparation steps.
• Better case-cart logistics.
• Consistent fill volumes.
• Reliable backorder performance.
• Contracting across MRI and CT contrast portfolios.

The business case is strongest when a supplier can offer MultiHance-equivalent product alongside iodinated contrast and other gadolinium agents. Hospitals often prefer portfolio vendors that simplify procurement and supply management.

Manufacturing and supply-chain opportunities

The formulation’s simplicity allows cost reduction through process control rather than excipient redesign. Potential advantages include:

• High-yield chelate synthesis.
• Improved purification of gadobenate dimeglumine.
• Closed-system sterile filling.
• Dual-source raw materials.
• Regional fill-finish capacity.
• Automated visual inspection.
• Lower extractables packaging components.
• Robust cold-chain and ambient-shipping qualification.

For contract manufacturers, the principal barrier is validated sterile injectable capability and reliable access to high-purity gadolinium-chelate active pharmaceutical ingredient.

How does MultiHance compare with competing gadolinium agents?

MultiHance competes with gadobutrol, gadoterate meglumine, gadoteridol, gadopentetate dimeglumine, and other gadolinium-based contrast agents. Competitive positioning depends on indication, imaging protocol, safety profile, dose, price, and institutional preference.

Product class	Active agent	Commercial positioning
MultiHance	Gadobenate dimeglumine	High-relaxivity gadolinium agent with established CNS, breast, and vascular uses
Gadavist	Gadobutrol	Broad MRI use and high-concentration formulation
Dotarem	Gadoterate meglumine	Macrocyclic agent with strong stability positioning
ProHance	Gadoteridol	Macrocyclic agent with established MRI use
Magnevist	Gadopentetate dimeglumine	Older linear agent with declining use in many markets

Macrocyclic agents may have an advantage in institutional safety positioning because of greater thermodynamic and kinetic stability relative to older linear agents. MultiHance’s commercial position depends on approved indications, diagnostic performance, local guidelines, supply, and price.

A generic MultiHance entrant would need a clear reason for selection against macrocyclic alternatives. Price and availability are the most credible differentiators. Excipient novelty is unlikely to alter prescribing behavior.

What patent litigation and settlement issues affect MultiHance?

Patent litigation risk should be evaluated at the application and claim level rather than inferred from the age of the product. The relevant events include:

• Paragraph IV notice letters.
• District court infringement complaints.
• Patent-term adjustments.
• ANDA litigation settlements.
• Launch-at-risk decisions.
• Authorized-generic arrangements.
• Licensing agreements covering specific territories or indications.

No biosimilar litigation pathway applies because gadobenate dimeglumine is a chemically defined small molecule. Any U.S. challenge would proceed through the ANDA patent-certification framework or, in some cases, a 505(b)(2) strategy.

A settlement could delay generic entry, authorize an early launch, permit a licensee to enter under defined conditions, or resolve only a subset of indications. Commercial diligence must therefore distinguish between the earliest possible launch date and the earliest full-label launch date.

What licensing deals could create commercial value?

Potential licensing structures include:

• Regional rights to gadobenate dimeglumine.
• Authorized-generic supply agreements.
• API and finished-dose supply partnerships.
• Co-development of prefilled syringes.
• Hospital-channel distribution agreements.
• Portfolio deals combining MultiHance with other contrast agents.
• Manufacturing licenses for sterile fill-finish.
• Injector compatibility or device partnerships.

An authorized-generic agreement would offer the incumbent a way to manage price erosion while giving a partner access to an established product. A regional license could be attractive in markets where local registration, tender access, or manufacturing requirements create barriers to direct entry.

How strong is the MultiHance patent estate?

The patent estate is likely strongest around historical gadobenate chemistry, original medical uses, and manufacturing know-how. It is less likely to be strong around conventional excipients because the marketed formulation is simple and does not rely on a proprietary delivery platform.

Relative strength by asset type

Asset	Relative relevance
Original active-ingredient patents	Historically important, but age limits remaining exclusivity
Specific imaging-use claims	Potentially relevant to label strategy
Process patents	Can affect API sourcing and cost
Excipient patents	Likely limited unless tied to a specific stability or presentation claim
Packaging patents	Relevant to prefilled or injector-compatible products
Trade secrets	Potentially important for scale-up, purification, and sterile filling
Regulatory exclusivity	Historical rather than a current primary barrier

The practical strength of the estate depends on live claims, jurisdiction, prosecution history, ownership, licensing, and enforceability. A company entering the market should place greater emphasis on a current patent-and-litigation review than on the existence of old composition patents.

Key Takeaways

• MultiHance uses a simple aqueous injectable formulation centered on gadobenate dimeglumine and water for injection.
• Excipient substitution is unlikely to create meaningful differentiation.
• The main development barriers are chelate quality, free-gadolinium control, sterility, stability, container closure, and injector compatibility.
• The product’s U.S. regulatory exclusivity is historical; current entry risk depends primarily on live patent listings and use claims.
• No biosimilar pathway applies.
• The most attractive commercial opportunities are generic entry, authorized-generic supply, prefilled or workflow-optimized presentations, and hospital portfolio contracting.
• Manufacturing reliability and supply continuity may create more value than formulation novelty.
• A successful entrant will likely compete on cost, waste reduction, availability, and procurement simplicity.

FAQs

Can MultiHance be reformulated with a different buffer?

Yes, but a buffer change could affect pH, osmolality, stability, tolerability, and regulatory comparability. A formulation closely matching the reference product generally presents the lower-risk development path.

Is gadobenate dimeglumine a macrocyclic gadolinium agent?

No. Gadobenate dimeglumine is a linear ionic gadolinium chelate. Its stability and safety profile should be assessed separately from macrocyclic agents such as gadobutrol, gadoterate, and gadoteridol.

Could a generic MultiHance product use a prefilled syringe?

Potentially. The format would require compatibility studies covering the syringe barrel, stopper, lubricant, extractables, leachables, storage stability, dose delivery, and automated injector performance.

Are excipient patents the main barrier to MultiHance competition?

No. The main barriers are active-ingredient sourcing, sterile injectable manufacturing, quality control, regulatory equivalence, hospital contracting, and any surviving method-of-use or process patents.

What is the most defensible commercial differentiation for a MultiHance competitor?

Lower total treatment cost, reduced vial waste, reliable supply, compatible high-throughput packaging, and integrated contracting with other imaging contrast products are more defensible than adding a conventional excipient.

References

1. U.S. Food and Drug Administration. (2023). MultiHance (gadobenate dimeglumine) injection: Prescribing information. Bracco Diagnostics Inc.

2. National Library of Medicine. (n.d.). DailyMed: MultiHance - gadobenate dimeglumine injection. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Center for Drug Evaluation and Research.